The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial.
 
Sandra P. D'Angelo
Honoraria - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; SERVIER
Consulting or Advisory Role - AADi; Adaptimmune; GI Innovation; GlaxoSmithKline; Incyte; Nektar; Pfizer; Rain Therapeutics; Servier
Research Funding - Amgen; Bristol-Myers Squibb.; Deciphera; EMD Serono; Incyte; Merck; Nektar
Travel, Accommodations, Expenses - Adaptimmune; EMD Serono; Nektar
Other Relationship - Adaptimmune; GlaxoSmithKline; Merck; Nektar
 
Andrew James Scott Furness
Employment - The Royal Marsden NHS Foundation Trust
Consulting or Advisory Role - Achilles Therapeutics; GlaxoSmithKline; Immunocore; Neogene Therapeutics
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck; Pfizer
Patents, Royalties, Other Intellectual Property - WO2019008375A1
Travel, Accommodations, Expenses - Achilles Therapeutics; Adaptimmune; ESMO; Iovance Biotherapeutics
 
Fiona Thistlethwaite
Honoraria - Bayer
Consulting or Advisory Role - Bristol-Myers Squibb; Enara Bio; GlaxoSmithKline; Guidepoint Pharmacy; Immatics; Ixaka; Janssen; Leucid Bio; Pfizer (Inst); Scenic Biotech; T-Knife
Research Funding - 3-V Biosciences (Inst); Abbvie (Inst); Actuate Therapeutics (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agalimmune (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); BerGenBio (Inst); Blueprint Medicines (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GenMab (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immutep (Inst); Incyte (Inst); Janssen (Inst); kinex (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millenium Pharamceuticals (Inst); MSD (Inst); Novartis (Inst); Octimet (Inst); Orion (Inst); Pfizer (Inst); Redx Pharma (Inst); Roche (Inst); Roche (Inst); Sierra Oncology (Inst); Synthon (Inst); Takeda (Inst); Tarveda Therapeutics (Inst)
Travel, Accommodations, Expenses - Ixaka; Scenic Biotech
Other Relationship - iMatch
 
Melissa Amber Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Consulting or Advisory Role - Rain Therapeutics; SpringWorks Therapeutics
Research Funding - Merck
 
Richard F. Riedel
Employment - Limbguard (I)
Leadership - Limbguard (I)
Stock and Other Ownership Interests - Limbguard (I)
Consulting or Advisory Role - AADi; Adaptimmune; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; GlaxoSmithKline; NanoCarrier; SpringWorks Therapeutics
Research Funding - AADi (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Cogent Biosciences (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); NanoCarrier (Inst); Oncternal Therapeutics (Inst); Philogen (Inst); PTC Therapeutics (Inst); SpringWorks Therapeutics (Inst); TRACON Pharma (Inst); Trillium Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - PandoNet - Limbguard (I)
Travel, Accommodations, Expenses - Daiichi Sankyo; Deciphera; NanoCarrier; SpringWorks Therapeutics
 
John Haanen
Stock and Other Ownership Interests - Neogene Therapeutics
Consulting or Advisory Role - Achilles Therapeutics (Inst); bioNTech (Inst); Bristol-Myers Squibb (Inst); CureVac; Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Ipsen (Inst); Molecular Partners (Inst); MSD Oncology (Inst); Neogene Therapeutics; Novartis (Inst); Pfizer (Inst); POEM Health (Inst); Roche/Genentech (Inst); Sanofi (Inst); T-Knife (Inst); Third Rock Ventures (Inst)
Research Funding - Amgen (Inst); Asher Biotherapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Neon Therapeutics (Inst); Novartis (Inst)
 
Jonathan Noujaim
No Relationships to Disclose
 
Anna Weinberg Chalmers
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo/Lilly; DePuy Companies (I); ExacTech (I)
Speakers' Bureau - SpringWorks Therapeutics
Research Funding - BioAtla; Boehringer Ingelheim; GlaxoSmithKline; TRACON Pharma
Patents, Royalties, Other Intellectual Property - patent pending for hormone supplementation of tendon and ligament repair (I)
 
Antonio López Pousa
No Relationships to Disclose
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; InhibRx; Jazz Pharmaceuticals; SpringWorks Therapeutics
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Cogent Biosciences (Inst); Cornerstone Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Janssen (Inst); Kronos Bio (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
 
Lara E. Davis
Consulting or Advisory Role - Daiichi Sankyo; InhibRx; Regeneron; SpringWorks Therapeutics
Research Funding - Adaptimmune (Inst); Bayer (Inst); BioAtla (Inst); BTG (Inst); Eisai (Inst); Epizyme (Inst); InhibRx (Inst); Novartis (Inst); Salarius Pharmaceuticals (Inst); SpringWorks Therapeutics (Inst)
 
Edouard Forcade
Speakers' Bureau - Alexion Pharmaceuticals; Astellas Pharma; Gilead Sciences; GlaxoSmithKline; Novartis; Sanofi
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Gilead Sciences; Novartis; Sanofi
 
Mark Agulnik
Consulting or Advisory Role - AADi; Boehringer Ingelheim
Speakers' Bureau - Deciphera
Research Funding - Exelixis (Inst)
 
Dennis Williams
Employment - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune
 
Mary A. Woessner
Employment - GlaxoSmithKline; GlaxoSmithKline (I)
Stock and Other Ownership Interests - GlaxoSmithKline; GlaxoSmithKline (I)
Travel, Accommodations, Expenses - GlaxoSmithKline; GlaxoSmithKline (I)
 
Thomas Faitg
Employment - GlaxoSmithKline
 
Beth Ireland
Employment - Adaptimmune
 
Michael Jason Nathenson
Employment - Adaptimmune; GlaxoSmithKline
Stock and Other Ownership Interests - Bristol-Myers Squibb; Johnson & Johnson; Merck
Expert Testimony - US DOJ; US DOJ
 
Elliot Norry
Employment - Adaptimmune
Leadership - Adaptimmune
Stock and Other Ownership Interests - Adaptimmune; GlaxoSmithKline
 
Albiruni Ryan Abdul Razak
Consulting or Advisory Role - Adaptimmune; GlaxoSmithKline; Inhibrx; Medison
Research Funding - 23 and Me; Abbvie; Adaptimmune; Amgen; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Deciphera; Frontier Therapeutics; GlaxoSmithKline; Iterion Therapeutics; Karyopharm Therapeutics; MedImmune; Merck; Neoleukin Therapeutics; Pfizer; Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison